<DOC>
	<DOCNO>NCT01051011</DOCNO>
	<brief_summary>This randomize , open-label , parallel arm study compare safety , tolerability effect glycemic control taspoglutide versus insulin glargine insulin-naïve patient type 2 diabetes mellitus inadequately control merformin sulfonylurea combination therapy . Patients randomize receive either taspoglutide 10mg subcutaneously ( sc ) weekly , taspoglutide 10mg sc weekly 4 week follow 20mg sc weekly , insulin glargine initial dose 10 international unit sc daily . Metformin treatment continue patient throughout study , whereas sulfonylurea discontinue start study treatment . Anticipated time study treatment 24 week , option continue assign treatment another 28 week . Target sample size 500-600 patient .</brief_summary>
	<brief_title>A Study Compare Taspoglutide Insulin Glargine Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled Metformin Sulfonylurea Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age type 2 diabetes mellitus , treat stable dose metformin sulfonylurea &gt; /= 12 week prior screen HbA1c 710 % screen body weight stable ( +/5 % ) &gt; /= 12 week prior screen fast Cpeptide &gt; /=1ng/ml treatmentnaïve insulin diagnosis history type 1 diabetes mellitus secondary form diabetes acute metabolic diabetic complication evidence clinically significant diabetic complication clinically symptomatic gastrointestinal disease history chronic pancreatitis acute idiopathic pancreatitis &gt; 3 episode severe hypoglycemia within 6 month prior screen miocardial infarcion , unstable angina pectoris , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within 6 month prior screen treatment exenatide , exendin analogue , GLP1 analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>